ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
아리피프라졸 시장 규모는 향후 수 년간 강력한 성장이 예상됩니다. 예측 기간의 성장은 우울증과 불안 장애의 이환율 상승, 맞춤형 의료의 중시, 제네릭 의약품의 광범위한 수용, 정신과 의약품 연구에 대한 투자 증가, 원격 정신 의료 및 디지털 르헬스 플랫폼의 확대가 견인할 것으로 예측됩니다. 예측 기간 중에 예측되는 주요 동향에는 장시간 작용형 주사 제제의 개발, 나노입자 기반의 약물전달 시스템의 진보, 어드히어런스 모니터링을 위한 디지털 툴의 도입, 신약에 있어서의 인공지능 이용, 배합과 모니터링을 위한 원격 의료의 통합 등이 있습니다.
정신 질환의 이환율 증가는 미래의 아리피프라졸 시장의 성장을 가속할 것으로 예측됩니다. 정신 질환은 개인의 생각, 감정, 행동 및 일상적인 기능에 영향을 미치는 다양한 정신 건강 상태를 포함합니다.만성 스트레스, 사회적 고립, 현대적인 라이프 스타일의 압박과 같은 요인은 이러한 장애의 발생률을 증가하고 있습니다. 아리피프라졸은 도파민과 세로토닌의 뇌 활동을 조절하여 정신 질환 치료를 지원하며, 이를 통해 조현병, 양극성 장애 및 주요 우울 장애를 관리하는 데 효과적입니다. 2022년 미국에 본사를 둔 연방 연구 기관인 국립 정신 건강 연구소는 2022년, 미국의 18세 이상의 성인 5,930만명이 정신 질환(AMI)을 경험했으며, 이것은 성인 인구의 23.1%에 해당한다고 보고했습니다. 그 결과, 정신 질환의 유병률 증가가 아리피프라졸 시장의 확대에 박차를 가하고 있습니다.
또한 건강 관리 지출 증가는 아리피프라졸 시장의 성장에 기여할 것으로 예측됩니다. 지속적인 치료, 투약, 장기 케어 전략을 필요로하는 만성 정신 질환의 부담 증가로 인한 건강 관리 자금 증가는 고급 치료 옵션에 대한 액세스를 개선하고, 약물의 안정적인 공급을 보장하고, 환자 케어의 질을 향상시켜, 아리피프라졸의 광범위한 도입을 지원합니다. 또한 장기적인 치료 프로그램에 자금을 지원하여 정신 질환을 앓고 있는 사람들의 결과를 개선함으로써 의료 시스템을 강화합니다. 2024년 12월 미국 연방 기관인 메디케어 및 메디케이드 서비스 센터(CMS)는 2023년 국민 보건 지출이 7.5% 증가하여 4조 9,000억 달러에 달했으며, 이는 국내총생산(GDP)의 17.6%를 차지한다고 밝혔습니다. 또한, 2023-2032년에 걸쳐, 연간 평균 의료비는 5.6% 증가하고, 의료비는 2022년의 GDP의 17.3%에서 2032년에는 19.7%로 상승할 것으로 예측되고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 아리피프라졸 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 아리피프라졸 시장 : 성장률 분석
세계의 아리피프라졸 시장 실적: 규모와 성장, 2019-2024년
세계의 아리피프라졸 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 아리피프라졸 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 아리피프라졸 시장 : 적응증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
정신분열증
양극성 장애
큰 우울증 장애
자폐증 스펙트럼 장애
세계의 아리피프라졸 시장 : 환자 인구 통계별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
소아환자
성인 환자
노인환자
세계의 아리피프라졸 시장 : 제형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
경구정
경구용액
주사제
세계의 아리피프라졸 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
세계의 아리피프라졸 시장 : 정신분열증 하위 세분화, 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
급성 정신분열증
정신분열증 유지치료
세계의 아리피프라졸 시장 : 쌍극성 장애별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
양극성 I형 장애
양극성 II형 장애
양극성 우울증
세계의 아리피프라졸 시장 : 큰 우울증 장애별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
치료 저항성 우울증
급성 우울증 장애
세계의 아리피프라졸 시장 : 자폐증 스펙트럼 장애별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
자폐증에 따른 좌절감
자폐증에 있어서의 공격적 행동
제7장 지역별/국가별 분석
세계의 아리피프라졸 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 아리피프라졸 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
아리피프라졸 시장 : 경쟁 구도
아리피프라졸 시장 : 기업 프로파일
Novartis AG
Teva Pharmaceutical Industries Ltd.
Hetero Drugs
Sun Pharmaceutical Industries Ltd.
Cipla Limited
제31장 기타 주요 기업 및 혁신 기업
Zydus Lifesciences
Neuland Laboratories Ltd.
Ipca Laboratories Limited
Jubilant Pharmova
MSN Laboratories Pvt. Ltd.
Harman Finochem Ltd.
SMS Pharmaceuticals
Erregierre SpA
Tiefenbacher API Ingredients GmbH & Co. KG
Alkem Laboratories Ltd.
Suraj Laboratories Pvt. Ltd
Octavius Pharma Pvt. Ltd.
Tooba Pharmaceuticals Private Limited
Senores Pharmaceuticals Pvt. Ltd.
Gonane Pharma
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
아리피프라졸 시장, 2029년 : 새로운 기회를 제공하는 국가
아리피프라졸 시장, 2029년 : 새로운 기회를 제공하는 부문
아리피프라졸 시장, 2029년 : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Aripiprazole is an antipsychotic drug that functions as a partial agonist at dopamine D2 and serotonin 5-hydroxytryptamine receptor 1A (5-HT1A) receptors, and as an antagonist at serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptors. It is primarily prescribed for the treatment of schizophrenia, bipolar disorder, and as an adjunct therapy for major depressive disorder. By modulating dopamine and serotonin levels in the brain, it helps alleviate symptoms such as hallucinations, delusions, and mood fluctuations.
The primary indications for aripiprazole include schizophrenia, bipolar disorder, major depressive disorder, and autism spectrum disorder. Schizophrenia is a long-term mental health condition characterized by hallucinations, delusions, and disorganized thinking, and aripiprazole aids in symptom control by balancing dopamine and serotonin activity in the brain. The medication is prescribed across a range of patient groups, including pediatric, adult, and geriatric populations. It is available in various dosage forms such as oral tablets, oral solutions, and injectable formulations, and is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The aripiprazole market research report is one of a series of new reports from The Business Research Company that provides aripiprazole market statistics, including aripiprazole industry global market size, regional shares, competitors with an aripiprazole market share, detailed aripiprazole market segments, market trends and opportunities, and any further data you may need to thrive in the aripiprazole industry. The aripiprazole market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The aripiprazole market size has grown strongly in recent years. It will grow from $7.04 billion in 2024 to $7.65 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth during the historic period can be attributed to the increasing prevalence of schizophrenia and bipolar disorders, heightened awareness of mental health issues, expanded off-label use of aripiprazole, a growing geriatric population, and rising healthcare spending.
The aripiprazole market size is expected to see strong growth in the next few years. It will grow to $10.53 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period is expected to be driven by the rising incidence of depression and anxiety disorders, a stronger emphasis on personalized medicine, broader acceptance of generic aripiprazole, increased investment in psychiatric drug research, and the expansion of telepsychiatry and digital health platforms. Key trends projected for the forecast period include the development of long-acting injectable formulations, progress in nanoparticle-based drug delivery systems, incorporation of digital tools for adherence monitoring, the use of artificial intelligence in drug discovery, and the integration of telemedicine for prescribing and monitoring.
The rising incidence of psychiatric disorders is anticipated to drive the growth of the aripiprazole market in the future. Psychiatric disorders encompass a variety of mental health conditions that influence an individual's thoughts, emotions, behaviors, and daily functioning. Factors such as chronic stress, social isolation, and the pressures of modern lifestyles are contributing to the increasing rates of these disorders. Aripiprazole supports the treatment of psychiatric conditions by regulating dopamine and serotonin activity in the brain, making it effective for managing schizophrenia, bipolar disorder, and major depressive disorder. It offers improved symptom control through flexible dosing options, promoting better treatment adherence and enhancing patients' overall quality of life. For example, in 2022, the National Institute of Mental Health, a U.S.-based federal research agency, reported that 59.3 million adults aged 18 and older in the United States experienced any mental illness (AMI), representing 23.1% of the adult population. Consequently, the growing prevalence of psychiatric disorders is fueling the expansion of the aripiprazole market.
An increase in healthcare expenditure is also expected to contribute to the growth of the aripiprazole market. Healthcare expenditure includes the total financial resources allocated to medical services, treatments, healthcare infrastructure, research, and public health efforts aimed at enhancing overall health outcomes. The rising need for healthcare spending stems from the growing burden of chronic mental health conditions, which necessitate continuous treatment, medication, and long-term care strategies. Increased healthcare funding supports the broader adoption of aripiprazole by improving access to advanced treatment options, ensuring a stable supply of medication, and enhancing the quality of patient care. It also bolsters healthcare systems by financing prolonged therapeutic programs, leading to improved outcomes for individuals with psychiatric conditions. For instance, in December 2024, the Centers for Medicare and Medicaid Services (CMS), a U.S.-based federal agency, stated that national health expenditures grew by 7.5% to $4.9 trillion in 2023, making up 17.6% of the gross domestic product (GDP). Moreover, from 2023 to 2032, average annual health expenditure is projected to increase by 5.6%, with healthcare spending expected to rise from 17.3% of GDP in 2022 to 19.7% in 2032. Thus, the growth in healthcare expenditure is driving the aripiprazole market forward.
Leading players in the aripiprazole market are focusing on innovation and securing regulatory approvals, such as product line extensions, to improve patient adherence, expand treatment applications, and retain market share after patent expirations. Product line extension involves introducing new variations of an existing product within the same brand, typically by modifying the formulation, dosage, packaging, or delivery method to meet evolving patient needs or broaden the product's reach, while maintaining the original compound. For instance, in September 2022, Otsuka Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, along with Lundbeck, a Denmark-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) acceptance for their New Drug Application (NDA) for a 2-month, ready-to-use, long-acting injectable formulation of aripiprazole. This treatment is intended for adults with schizophrenia and for maintenance monotherapy in bipolar I disorder. The formulation delivers a steady release of aripiprazole over time, enabling patients to receive treatment once every two months.
North America was the largest region in the aripiprazole market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in aripiprazole report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the aripiprazole market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The aripiprazole market consists of sales of oral tablets, orally disintegrating tablets, and long-acting injectable suspensions. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Aripiprazole Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on aripiprazole market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for aripiprazole ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The aripiprazole market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Indication: Schizophrenia; Bipolar Disorder; Major Depressive Disorder; Autism Spectrum Disorder
2) By Patient Demographics: Pediatric Patients; Adult Patients; Geriatric Patients
3) By Dosage Form: Oral Tablets; Oral Solution; Injectable
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Schizophrenia: Acute Schizophrenia; Maintenance Treatment for Schizophrenia
2) By Bipolar Disorder: Bipolar I Disorder; Bipolar II Disorder; Bipolar Depression
3) By Major Depressive Disorder: Treatment-Resistant Depression; Acute Major Depressive Disorder
4) By Autism Spectrum Disorder: Irritability Associated with Autism; Aggressive Behavior in Autism
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Aripiprazole Market Characteristics
3. Aripiprazole Market Trends And Strategies
4. Aripiprazole Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Aripiprazole Growth Analysis And Strategic Analysis Framework
5.1. Global Aripiprazole PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Aripiprazole Market Growth Rate Analysis
5.4. Global Aripiprazole Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Aripiprazole Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Aripiprazole Total Addressable Market (TAM)
6. Aripiprazole Market Segmentation
6.1. Global Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Schizophrenia
Bipolar Disorder
Major Depressive Disorder
Autism Spectrum Disorder
6.2. Global Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric Patients
Adult Patients
Geriatric Patients
6.3. Global Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Tablets
Oral Solution
Injectable
6.4. Global Aripiprazole Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.5. Global Aripiprazole Market, Sub-Segmentation Of Schizophrenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Schizophrenia
Maintenance Treatment For Schizophrenia
6.6. Global Aripiprazole Market, Sub-Segmentation Of Bipolar Disorder, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bipolar I Disorder
Bipolar II Disorder
Bipolar Depression
6.7. Global Aripiprazole Market, Sub-Segmentation Of Major Depressive Disorder, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Treatment-Resistant Depression
Acute Major Depressive Disorder
6.8. Global Aripiprazole Market, Sub-Segmentation Of Autism Spectrum Disorder, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Irritability Associated With Autism
Aggressive Behavior In Autism
7. Aripiprazole Market Regional And Country Analysis
7.1. Global Aripiprazole Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Aripiprazole Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Aripiprazole Market
8.1. Asia-Pacific Aripiprazole Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Aripiprazole Market
9.1. China Aripiprazole Market Overview
9.2. China Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Aripiprazole Market
10.1. India Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Aripiprazole Market
11.1. Japan Aripiprazole Market Overview
11.2. Japan Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Aripiprazole Market
12.1. Australia Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Aripiprazole Market
13.1. Indonesia Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Aripiprazole Market
14.1. South Korea Aripiprazole Market Overview
14.2. South Korea Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Aripiprazole Market
15.1. Western Europe Aripiprazole Market Overview
15.2. Western Europe Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Aripiprazole Market
16.1. UK Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Aripiprazole Market
17.1. Germany Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Aripiprazole Market
18.1. France Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Aripiprazole Market
19.1. Italy Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Aripiprazole Market
20.1. Spain Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Aripiprazole Market
21.1. Eastern Europe Aripiprazole Market Overview
21.2. Eastern Europe Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Aripiprazole Market
22.1. Russia Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Aripiprazole Market
23.1. North America Aripiprazole Market Overview
23.2. North America Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Aripiprazole Market
24.1. USA Aripiprazole Market Overview
24.2. USA Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Aripiprazole Market
25.1. Canada Aripiprazole Market Overview
25.2. Canada Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Aripiprazole Market
26.1. South America Aripiprazole Market Overview
26.2. South America Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Aripiprazole Market
27.1. Brazil Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Aripiprazole Market
28.1. Middle East Aripiprazole Market Overview
28.2. Middle East Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Aripiprazole Market
29.1. Africa Aripiprazole Market Overview
29.2. Africa Aripiprazole Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Aripiprazole Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Aripiprazole Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Aripiprazole Market Competitive Landscape And Company Profiles
30.1. Aripiprazole Market Competitive Landscape
30.2. Aripiprazole Market Company Profiles
30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Hetero Drugs Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis
31. Aripiprazole Market Other Major And Innovative Companies
31.1. Zydus Lifesciences
31.2. Neuland Laboratories Ltd.
31.3. Ipca Laboratories Limited
31.4. Jubilant Pharmova
31.5. MSN Laboratories Pvt. Ltd.
31.6. Harman Finochem Ltd.
31.7. SMS Pharmaceuticals
31.8. Erregierre S.p.A.
31.9. Tiefenbacher API + Ingredients GmbH & Co. KG
31.10. Alkem Laboratories Ltd.
31.11. Suraj Laboratories Pvt. Ltd
31.12. Octavius Pharma Pvt. Ltd.
31.13. Tooba Pharmaceuticals Private Limited
31.14. Senores Pharmaceuticals Pvt. Ltd.
31.15. Gonane Pharma
32. Global Aripiprazole Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Aripiprazole Market
34. Recent Developments In The Aripiprazole Market
35. Aripiprazole Market High Potential Countries, Segments and Strategies
35.1 Aripiprazole Market In 2029 - Countries Offering Most New Opportunities
35.2 Aripiprazole Market In 2029 - Segments Offering Most New Opportunities
35.3 Aripiprazole Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
